Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Current Deferred Revenue (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Current Deferred Revenue for 6 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a N/A change, with the full-year FY2025 number at $4.2 million, changed N/A from a year prior.
  • Current Deferred Revenue was $4.2 million for Q4 2025 at Crescent Biopharma, up from $74072.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $4.2 million in Q4 2025 to a low of $4.2 million in Q4 2025.